A detailed history of E. Ohman J:Or Asset Management Ab transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, E. Ohman J:Or Asset Management Ab holds 10,310 shares of VRTX stock, worth $4.79 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
10,310
Previous 11,060 6.78%
Holding current value
$4.79 Million
Previous $5.18 Billion 7.51%
% of portfolio
0.12%
Previous 0.13%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$460.0 - $505.78 $345,000 - $379,335
-750 Reduced 6.78%
10,310 $4.79 Billion
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $219,973 - $271,896
560 Added 5.33%
11,060 $5.18 Billion
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $203,845 - $223,040
500 Added 5.0%
10,500 $4.39 Billion
Q4 2023

Feb 15, 2024

SELL
$343.0 - $410.68 $651,700 - $780,292
-1,900 Reduced 15.97%
10,000 $4.07 Billion
Q3 2023

Feb 06, 2024

BUY
$338.18 - $362.46 $4.02 Million - $4.31 Million
11,900 New
11,900 $4.14 Billion
Q3 2022

Apr 05, 2024

SELL
$273.83 - $305.53 $3.04 Million - $3.39 Million
-11,100 Closed
0 $0
Q2 2022

Apr 05, 2024

SELL
$234.96 - $292.55 $46,992 - $58,510
-200 Reduced 1.77%
11,100 $3.13 Billion
Q1 2022

Apr 05, 2024

SELL
$221.42 - $260.97 $332,130 - $391,455
-1,500 Reduced 11.72%
11,300 $2.95 Billion
Q4 2021

Apr 05, 2024

BUY
$177.01 - $223.45 $159,309 - $201,105
900 Added 7.56%
12,800 $2.81 Billion
Q2 2021

Apr 05, 2024

SELL
$187.49 - $221.1 $30.4 Million - $35.9 Million
-162,150 Reduced 93.16%
11,900 $2.4 Billion
Q1 2021

Apr 05, 2024

BUY
$207.02 - $241.31 $33.8 Million - $39.4 Million
163,250 Added 1511.57%
174,050 $37.4 Billion
Q3 2020

Apr 05, 2024

BUY
$255.65 - $303.1 $204,520 - $242,480
800 Added 8.0%
10,800 $2.94 Billion
Q2 2020

Apr 05, 2024

BUY
$225.48 - $295.8 $248,028 - $325,380
1,100 Added 12.36%
10,000 $2.9 Billion
Q1 2020

Apr 05, 2024

SELL
$199.77 - $247.81 $679,218 - $842,554
-3,400 Reduced 27.64%
8,900 $2.12 Billion
Q4 2019

Apr 05, 2024

BUY
$166.71 - $223.91 $2.05 Million - $2.75 Million
12,300 New
12,300 $2.69 Billion
Q2 2018

Apr 05, 2024

SELL
$145.72 - $169.96 $859,748 - $1 Million
-5,900 Closed
0 $0
Q1 2018

Apr 05, 2024

SELL
$151.6 - $177.13 $90,960 - $106,278
-600 Reduced 9.23%
5,900 $962 Million
Q3 2017

Apr 05, 2024

BUY
$148.13 - $162.24 $29,626 - $32,448
200 Added 3.17%
6,500 $988 Million
Q1 2017

Apr 05, 2024

BUY
N/A
800 Added 14.55%
6,300 $689 Million
Q3 2016

Apr 05, 2024

BUY
N/A
1,300 Added 30.95%
5,500 $480 Million
Q1 2016

Apr 05, 2024

SELL
N/A
-1,000 Reduced 19.23%
4,200 $334 Million
Q2 2013

Apr 05, 2024

SELL
N/A
-1,700 Reduced 24.64%
5,200 $416 Million
Q1 2013

Apr 05, 2024

BUY
N/A
2,300 Added 50.0%
6,900 $379 Million
Q2 2010

Apr 05, 2024

BUY
N/A
2,100 Added 84.0%
4,600 $151 Million
Q4 2009

Apr 05, 2024

SELL
N/A
-1,100 Reduced 30.56%
2,500 $107 Million
Q2 2009

Apr 05, 2024

BUY
N/A
1,800 Added 100.0%
3,600 $128 Million
Q4 2006

Apr 05, 2024

SELL
N/A
-8,200
1,800 $67.4 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track E. Ohman J:Or Asset Management Ab Portfolio

Follow E. Ohman J:Or Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.